Despite its latest FDA scandal, Gilead Sciences filed a New Drug Application to Japan’s Ministry of Health, Labour and Welfare, who approved the company’s once daily oral tablet hepatitis C treatment.
Harvoni, the name of the mediation, along with Gilead’s other hepatitis C treatment regiment Sovaldi, represent about 60% of the company’s revenue, and they hope to see an increase in their stocks as this project moves forward.
The company expects a 9.3% increase in stocks, and analysts are speculating that this move may just be what puts Gilead back on the market. Harvoni and Sovaldi have always been Gilead’s saving graces, and being top of the line in class regimens, it was only to be expected that these two medications would be what saved them from the inevitable plummet caused by their most recent run-in with the US FDA.
